Sun Pharma gains on higher prices for drugs
Reuters Market Eye - Shares in Sun Pharmaceutical Industries(SUN.NS) gain 1.8 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries (TARO.N) has pushed through price increases in three products last week, citing industry checks.
Credit Suisse estimates those three drugs account for 35 percent of Taro U.S. sales.
The price increases raise sustainable sales estimates for Taro to $680 million versus $640 million earlier for FY 2015, the investment bank adds.
Credit Suisse maintains its "outperform" rating on the stock and raises its target price to 900 rupees from 840 rupees, in part by factoring higher sales estimates for Taro.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
Trending On Reuters
South Asian leaders will pile pressure on Pakistan on Thursday to salvage a summit in Nepal by agreeing to electricity sharing and the free movement of vehicles across borders, measures aimed at boosting trade among nearly a quarter of the world's people. Full Article
Disputes over land for industry on the rise in India, angering locals - charities Full Article